Replies to post #268416 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Amazing highlight!

[sentiment_stocks]

Thanks Lykiri... excellent find.

From Richard Pazdur's slides:

No Free Lunch: Strengths and Limitations of Endpoints

Overall Survival:
Clinical Outcome (biggest plus);
Low Risk of Bias (biggest plus);
Feasibility - biggest minus

and

Paradigm Shift?
Location, Location, Location --- to --- Biomarker, Biomarker, Biomarker

Prerequisite: detailed biologic understanding + clinical data showing large magnitude and consistency of effect in patients with rare & refractory cancers, limited therapeutic options, unmet need

and

Personalized Cancer Therapy

https://cddf.org/wp-content/uploads/2020/02/0945_Richard-Pazdur.pdf